Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,184.69
+5.76 (+0.49%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
April 25, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
April 24, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
2 Small-Cap Growth Stocks With Room To Run
April 24, 2024
These two small-cap growth stocks could be ready to run.
Via
The Motley Fool
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
April 22, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
April 18, 2024
Via
Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 Today
April 17, 2024
Via
Benzinga
Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views
April 12, 2024
Via
Benzinga
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
April 18, 2024
From
Kirby McInerney LLP
Via
GlobeNewswire
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm
April 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
April 17, 2024
Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300...
Via
Benzinga
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking
April 11, 2024
Via
Benzinga
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
March 28, 2024
Via
Benzinga
Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals
March 26, 2024
Via
Benzinga
The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
April 17, 2024
From
Law Offices of Frank R. Cruz
Via
Business Wire
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
April 12, 2024
The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears.
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug
April 11, 2024
The U.S. Justice Department accuses Regeneron Pharmaceuticals of Medicare fraud related to its macular degeneration drug, Eylea. Allegations include manipulating drug prices, resulting in inflated...
Via
Benzinga
Topics
Fraud
Exposures
Legal
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in Friday Morning Trading
March 22, 2024
Via
Investor Brand Network
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
April 11, 2024
From
Schall Law
Via
GlobeNewswire
Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?
April 11, 2024
Regeneron has fallen more than 6% over the past six weeks, and dropped again Thursday, as the DOJ focuses on its Eylea franchise.
Via
Investor's Business Daily
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
April 07, 2024
Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Should You Sell This Stock Following a Regulatory Roadblock?
April 05, 2024
It's not the first such obstacle this high-performing drugmaker has faced.
Via
The Motley Fool
5 Healthcare Stocks to Buy for 2024
April 02, 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
April 01, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today
April 01, 2024
Via
Benzinga
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Via
Investor's Business Daily
Exposures
Product Safety
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
March 28, 2024
Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense.
Via
The Motley Fool
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
March 26, 2024
These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run.
Via
InvestorPlace
FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns
March 25, 2024
The FDA issues complete response letters to Regeneron Pharmaceuticals Inc's BLA for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, requesting more trial data...
Via
Benzinga
Exposures
Product Safety
Regeneron Provides Update on Biologics License Application for Odronextamab
March 25, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
March 22, 2024
The market for weight loss drug stocks is massive, and these three companies could be the biggest beneficiaries of this trend.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.